(Q51469005)

English

Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.

scientific article published in July 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17587393

Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. (English)

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17587393

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Ristic S

1

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17587393

Collober-Maugeais C

2

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17587393

Cressier F

3

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17587393

Tang P

4

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17587393

Pecher E

5

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17587393

publication date

1 July 2007

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17587393

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17587393

9

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17587393

4

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17587393

506-511

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17587393

Global and societal implications of the diabetes epidemic

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00632.X

21 January 2018

Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00632.X

21 January 2018

Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00632.X

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00632.X

21 January 2018

Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00632.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2006.00632.X

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17587393

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17587393

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51469005&oldid=1569860425"